[Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders].

Alina Lozinski*, Sharon Baum, Lior Sagi, Alex Volkov, Henri Trau, Aviv Barzilai

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Autoimmune bullous skin disorders are characterized by a severe and potentially lethal course and may require aggressive long-term treatment with systemic corticosteroids and other immunosuppressive drugs, which can lead to serious adverse events. Recently, anti-CD20 antibody, Rituximab, was reported to be beneficial as an adjuvant therapy in these diseases. Herein, we present 2 case reports of patients suffering from resistant rare diseases from the aforementioned spectrum: linear IgA dermatosis and Pemphigoid gestationis. The patients were successfully treated with Rituximab (Mabthera). This is one of the first reports of this kind of treatment for these rare life-threatening diseases. These case reports emphasize the role of Rituximab as a crisis therapy in autoimmune blistering diseases.

Original languageEnglish
Pages (from-to)562-565, 606
JournalUnknown Journal
Issue number10
StatePublished - Oct 2012


Dive into the research topics of '[Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders].'. Together they form a unique fingerprint.

Cite this